At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 4, 2026 at 16:20 ET
Scynexis reported a significant year-over-year revenue increase to $20.6 million in 2025, driven by a $24.8 million one-time payment and catchup revenue from GSK, while R&D and SG&A expenses declined. The company ended the year with $56.3 million in cash, providing a runway of over two years, and advanced its SCY-247 program with Phase 1 IV dosing initiated and expanded access planned for 2026.
- Revenue surged to $20.6 million in 2025 from $3.7 million in 2024, primarily due to $24.8 million in non-refundable payments and catchup revenue from GSK.
- Net loss narrowed to $8.6 million from $21.3 million in 2024, with R&D expenses decreasing 15.6% year-over-year.
- Cash, cash equivalents, and investments totaled $56.3 million as of December 31, 2025, providing a cash runway of more than two years.
- SCY-247 IV formulation Phase 1 dosing initiated in February 2026, with topline data expected in second half of 2026; expanded access program planned for first half of 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access